T-1201

T-1201 is a first-in-class small molecule drug conjugate (SMDC) developed for oncology indications. It specifically targets the cell surface marker phosphatidylserine, which is exposed on cancer cells, allowing for precise identification and targeting of malignant cells. The drug utilizes SN-38, the active metabolite of irinotecan and a potent cytotoxic agent, as its payload. Its mechanism of action is similar to that of antibody-drug conjugates but uses a small molecule scaffold instead. Preclinical studies have demonstrated superior potency compared to irinotecan with reduced toxicity in various xenograft models including colorectal, pancreatic, prostate, lung, breast, and liver cancers. T-1201, developed by Taivex Therapeutics, is currently being evaluated in Phase I clinical trials for safety and tolerability in patients with advanced solid tumors.